Cell cycle deregulation is a common feature of human cancer. Tumor cells accumulate mutations that result in unscheduled proliferation, genomic instability and chromosomal instability. Several therapeutic strategies have been proposed for targeting the cell division cycle in cancer. Whereas inhibiting the initial phases of the cell cycle is likely to generate viable quiescent cells, targeting mitosis offers several possibilities for killing cancer cells. Microtubule poisons have proved efficacy in the clinic against a broad range of malignancies, and novel targeted strategies are now evaluating the inhibition of critical activities, such as cyclin-dependent kinase 1, Aurora or Polo kinases or spindle kinesins. Abrogation of the mitotic checkpoint or targeting the energetic or proteotoxic stress of aneuploid or chromosomally instable cells may also provide further benefits by inducing lethal levels of instability. Although cancer cells may display different responses to these treatments, recent data suggest that targeting mitotic exit by inhibiting the anaphase-promoting complex generates metaphase cells that invariably die in mitosis. As the efficacy of cell–cycle targeting approaches has been limited so far, further understanding of the molecular pathways modulating mitotic cell death will be required to move forward these new proposals to the clinic.
Extensive understanding of cell cycle regulation has led to the proposal of new strategies for cancer therapy.
Targeting regulators of centrosome duplication and separation, spindle formation and mitotic checkpoint have demonstrated efficacy in preclinical models but limited activity in clinical trials.
The balance between mitotic cell death pathways and kinetics of cyclin B1 degradation determines the therapeutic effectiveness of antimitotic-based strategies.
Targeting mitotic exit has been proposed as a better therapeutic strategy than targeting spindle assembly and spindle regulators.
Sustained mitotic arrest leads to a poorly characterized cell death, which may be modulated by cyclin-dependent kinase 1 (Cdk1) activity.
Why new mitotic inhibitors have demonstrated limited activity in vivo in comparison with classical microtubule-targeting drugs?
Newly proposed strategies need to be validated in vivo before reaching clinical settings.
We need to understand in detail the molecular mechanisms that govern mitotic cell death. Can modulation of these cell death pathways synergize with current antimitotic drugs?
We need to identify and characterize specific biomarkers for a better definition of patients that may benefit from therapeutic strategies targeting mitosis.
The cell cycle is deregulated in most cancer cells, and multiple strategies have been proposed in the last years to impair tumor cell proliferation. Initial strategies were designed to inhibit the machinery that drives the entry into the cell cycle (G1 phase) and DNA synthesis (S phase). The discovery of centrosomal and mitotic regulators that function during S phase, G2 (a preparatory phase for mitosis (M)) or M phase later provided additional targets, such as mitotic kinases or the mitotic spindle machinery, required for chromosome segregation. The promise of these targets was reinforced by the clinical success of microtubule poisons such as Vinca alkaloids or taxanes. However, targeted therapies directed against the cell cycle have shown limited clinical effect so far. A crucial question in these studies is to what extent targeting the cell cycle merely results in proliferative arrest or induces tumor cell death, and which are the major resistance mechanisms. Recent studies suggest that delaying mitosis or preventing mitotic exit may be highly efficient in killing tumor cells. We will review here current strategies to kill proliferating cells, with specific focus on targeting mitosis or mitotic exit.
Cell Cycle Entry
Progression through the mammalian cell cycle is driven by several enzymatic activities including protein kinases. Among them, Cdks are heterodimeric protein kinases composed of a catalytical subunit, called Cdk, and a regulatory subunit, known as cyclin. These complexes are activated sequentially to drive cells through the cell cycle. Whereas Cdk2, Cdk4 and Cdk6 trigger G1/S transition, Cdk1 promotes mitotic entry.1 On the one hand, the activity of Cdks is frequently deregulated in tumor cells due to epigenetic or genetic alterations of Cdk–cyclin complexes or to downregulation of several Cdk inhibitors.2 Most human tumors display alterations in these regulators, and interphase Cdks were soon identified as possible anticancer targets.2, 3 However, the first generation of pan-Cdk inhibitors, such us flavopiridol and UCN-01, did not show clinical advantages due to its side effects.4 The analysis of gene-targeted mouse models indicated that Cdk2, Cdk4 and Cdk6 are only essential for the proliferation of some specialized cells, suggesting that Cdk inhibitors are likely to produce certain toxicities by affecting specific cells.3, 5, 6, 7 Nonetheless, Cdk4 inhibition may be effective to prevent Myc-induced skin tumors,8 Ras-induced breast cancer9 or K-Ras-induced non-small-cell lung carcinoma.10 These results suggest that Cdk inhibition may be exploited in clinical settings taking into consideration the cellular context of the tumor and the pathogenic spectrum of their mutations.
Mechanistically, inhibition of cell cycle entry (e.g., by inhibiting interphase Cdks) is likely to induce cell cycle arrest or quiescence but not apoptosis. The use of small-molecule inhibitors for interphase Cdks may result in certain levels of apoptosis, although the lack of specificity of these compounds prevents any detailed molecular conclusion.2 Interfering with the G1/S machinery generally prevents DNA replication, thus rendering diploid, interphasic cells that cannot proliferate but are viable. For instance, inhibition of Cdk4 prevents the development of lung tumors induced by K-Ras oncogene by triggering senescence, a permanent arrest in G0/G1.10 Current data suggest that senescent cells may be cleared by an innate immune response, but the extent to which this may contribute to prevention of age-related pathologies and cancer is currently not clear.
Targeting Mitotic Entry
In contrast to interphase Cdks, Cdk1 is essential for the mammalian cell cycle, and inhibition of Cdk1 prevents entry into mitosis and arrest cells in G211 (Figure 1). Cdk1 binds to A- or B-type cyclins and phosphorylates more than 70 substrates to promote centrosome separation, chromosome condensation, nuclear envelope breakdown and mitotic entry.1 Strong inhibition of Cdk1 is therefore likely to be toxic for normal cells, preventing useful therapeutic concentrations.3 However, recent studies suggest the possible use of Cdk1 inhibitors in specific cellular settings. Cdk1 is implicated in DNA repair by homologous recombination, and it is essential for efficient formation of BRCA1 foci. Inhibition of poly(ADP-ribose) polymerase (PARP) results in increased dependency on homologous recombination for DNA repair, and is synthetically lethal with mutations in genes involved in this type of DNA repair such as BRCA.12 Partial inhibition of Cdk1 may therefore sensitize BRCA-proficient cancer cells to inhibit PARP, suggesting specific applications of Cdk-targeting compounds in cancer cells.13 Similar synthetic lethal interactions are likely to exist in other molecular pathways including combinational inhibition with GSK3β 14 or inhibition of Cdk1 in Myc-overexpressing tumors.15
In addition to Cdk1, few other targets exist whose inhibition may arrest cells in G2. Mastl, also known as Greatwall in flies and Xenopus, is a protein kinase required for inhibiting PP2A phosphatases that dephosphorylate Cdk substrates.16, 17 Knockdown of Mastl results in G2 arrest and a variety of mitotic defects, and synergizes with Cdk1 inhibitors, suggesting that both kinases cooperate during mitotic entry.18, 19 Mastl may be an interesting target for cancer therapy, although the biology of this kinase remains to be studied and no specific inhibitors are available to date.
Targeting the Spindle Assembly
Mitotic drugs currently used in the clinic are microtubule poisons that perturb microtubule dynamics, impairing the formation of a proper bipolar spindle. Microtubule drugs are usually classified in two main groups: microtubule-destabilizing agents that inhibit microtubule polymerization and microtubule-stabilizing agents that enhance microtubule polymerization.20 Vinca alkaloids, such as vinblastine, vincristine, vinorelbine, vindesine and vinflunine, belong to destabilizing compounds and have shown clinical efficacy against a broad range of hematological malignancies. On the other hand, taxanes, such as docetaxel or paclitaxel, are microtubule-stabilizing drugs that are now widely used to treat breast and ovarian tumors, non-small-cell lung cancer and Kaposi's sarcoma.21 Both classes of drugs inhibit microtubule dynamics, impairing a functional spindle. This situation is monitored by a mitotic checkpoint, known as the spindle assembly checkpoint (SAC), that delays mitosis, providing cells with additional time to resolve errors in microtubule–kinetochore attachment.22, 23 The SAC inhibits the anaphase-promoting complex/cyclosome (APC/C), an E3-ubiquitin ligase that triggers mitotic exit mostly by targeting cyclin B for degradation, thus inhibiting Cdk1 activity. The SAC-dependent delay in mitosis increases the susceptibility of cells to undergo cell death. Alternatively, cells can escape from the mitotic arrest by slowly degrading cyclin B, a process known as mitotic slippage (see below; Figure 2).
Regardless of their effectiveness in cancer treatment, microtubule-targeted drugs exhibit important side effects. Patients treated with these drugs develop severe myelosuppression derived from proliferation impairment of cycling bone marrow cells. Neurotoxicity is also frequent due to the effects of these drugs on microtubules, which are basic components of neurons. In addition, patients treated with microtubule poisons often acquire resistance to these drugs.20 Thus, although inhibiting microtubule function has demonstrated a significant antitumor activity, the side effects of these drugs limit their use and have prompted to identify alternative antimitotic drugs.
New spindle targets
One of the key regulators of the spindle are kinesin motor proteins, which have crucial functions in spindle assembly, chromosome congression and segregation.24 Eg5 is a plus end-directed motor protein required for centrosome separation and thereby for building a bipolar spindle.25, 26 The growing interest of this kinesin as an antitumor target emerged from the pioneer identification of monastrol, the first small-molecule inhibitor of Eg5.27 Inhibition of Eg5 activity generates monopolar spindles that lead to mitotic arrest in a SAC-dependent manner.26, 27 This mitotic arrest culminates in cell death in a broad range of tumor cell lines, both in cell culture and xenografts,28, 29 and taxane-resistant cancer cells remain sensitive to Eg5 inhibition.30 As a consequence of these promising results, a number of Eg5 inhibitors have been studied, and some of them have recently entered into clinical trials31 (Table 1). Although side effects are moderate, the clinical efficacy of Eg5 inhibitors has been limited, with only few studies demonstrating a partial response.32
In addition to Eg5, kinesin CENP-E has recently emerged as a potential antitumoral target. This kinesin is also a plus end-directed motor protein that appears to have a pivotal role specifically in mitosis. CENP-E stabilizes the interactions between microtubules and kinetochores of the mitotic spindle33 and regulates the mitotic checkpoint by modulating the function of BubR1.34 CENP-E is an essential mammalian gene, and its complete inhibition leads to defective mitosis with unaligned chromosomes and apoptosis.35, 36 Partial inactivation of CENP-E has exhibited antitumor activity in xenografted human tumors, as well as in chemically-induced tumors in mice.36, 37 Farnesyl transferase inhibitors that hamper CENP-E activity and specific small-molecule inhibitors of CENP-E are currently in phase I of clinical trials32, 38 (Table 1).
In addition to kinesins, mitotic kinases such as Aurora A and Plk1 are also major regulators of spindle formation.16, 39, 40 These two mitotic kinases are overexpressed in cancer cells, often correlating with worse prognosis, and their inhibition results in mitotic defects, making them attractive mitotic targets.41, 42 As previously reported for Eg5, disruption of Plk1 or Aurora A activity results in SAC-dependent mitotic arrest as a consequence of monopolar spindle formation, and this arrest correlates with increased apoptosis in multiple cancer cell lines. Several ATP-competitive compounds specific against these kinases have already entered into clinical trials showing partial responses in specific tumors42, 43, 44 (Table 1). Further efforts are now dedicated to identify more specific compounds directed against the polo-box domain instead of the kinase domain of Plk1.44 Similarly to microtubule poisons, inhibition of these targets may result in apoptotic cell death or the generation of tetraploid cells through mitotic slippage. These tetraploid cells may be unable to replicate DNA in the following cell cycle if the corresponding checkpoints are functional or could eventually proliferate as polyploid cultures (Figure 2).
Targeting the Mitotic Checkpoint
To prevent chromosome missegregation, the SAC delays the metaphase–anaphase transition until all chromosomes are properly attached to microtubules.23 Abrogating the SAC therefore results in defective or abnormal chromosome segregation, generating polyploid or aneuploid cells (Box 1). It has been suggested that a partially compromised mitotic checkpoint may lead to chromosomal instability (CIN), therefore promoting tumorigenesis. Mice heterozygous for SAC components, such as Mad2 or BubR1, are prone to develop spontaneous tumors after long latencies.45, 46 In addition, mice with a weakened checkpoint due to partial loss of Bub3 or BubR1 also exhibit high rates of tumorigenesis after carcinogenic treatment.47, 48 Although these findings suggest a direct link between chromosome instability and tumorigenesis, mutations in mitotic checkpoint genes are not frequent in human tumors.49 This is not surprising taking into account the lethal phenotype observed after the complete abrogation of these genes in engineered mouse models.50
As most tumor cells are aneuploid or display certain levels of CIN (Box 1), it has been proposed that abrogating the SAC may induce further instability and may be therefore used as a therapeutic strategy. Genetic elimination of Mad2 or BubR1 results in widespread chromosome missegregation that trigger programmed cell death.45, 46, 48, 51 In contrast to other cell cycle checkpoints, the SAC is essential for cell survival, and targeting this mitotic checkpoint could constitute a novel strategy to kill tumor cells by inducing lethal instability.22, 52, 53 Inhibition of mitotic checkpoint activity by depletion of Mad2 or BubR1 provokes severe chromosome segregation errors that are incompatible with human cell viability.54, 55 In addition, reducing protein levels of BubR1 or Mps1, another protein kinase involved in the SAC, sensitizes tumor cells to taxol.53 Checkpoint abrogation by depletion of Mad2 or chemical inhibition of Mps1 have been evaluated as antitumor strategies in xenografted human tumors.56, 57 Aurora B may also be considered as a SAC target, as its downregulation overcomes the arrest in the presence of microtubule-stabilizing agents such as taxol.39, 58 Aurora B is required for embryo viability, and its genetic or chemical inhibition results in the generation of tetraploid cells with reduced viability, suggesting its relevance as a therapeutic target.59, 60
Interestingly, compared with non-transformed cells, cancer cell lines are more sensitive to undergo cell death in response to checkpoint abrogation.52, 61 Whether this is a consequence of the abnormal number of chromosomes commonly found in tumor cells (Box 1) is not well established. It has been proposed that, as a consequence of the extra chromosomes, tumor cells may require more time to properly align chromosomes at metaphase.62 This time requirement would make tumor cells more prone to chromosome missegregation and thereby more sensitive to die because of checkpoint abrogation. Other possible, although less explored, explanations for the increased susceptibility to the induction of CIN include differences in gene dosage or synthetic lethal interactions with deregulated pathways. Given the difficulties of reaching a complete inhibition of the mitotic checkpoint in vivo, a combination with sublethal doses of microtubule poisons has been suggested to achieve effective antitumor activities in clinical settings.53
Targeting Mitotic Exit
Mitotic slippage is thought to be one of the main mechanisms of resistance against antimitotic drugs63, 64, 65 (Figure 2). During a normal cell cycle, mitotic exit is driven by APC/C–Cdc20-dependent cyclin B1 degradation. Inhibiting mitotic progression triggers the SAC and inhibits APC/C–Cdc20. However, this inhibition is transient and slow, and progressive degradation of cyclin B1 may happen despite the unsatisfaction of the mitotic checkpoint.64, 65 Cells that escape from mitotic cell death can either die at the following cell cycle stage, arrest in a tetraploid state or undergo several rounds of division,63 depending of the status of genes such as p53 or p38 (Lanni et al.66; Rieder et al.67; Figure 2). Inhibition of apoptosis increases mitotic slippage,64, 68 suggesting that both processes are somehow linked (see below). Remarkably, several independent studies have observed no correlation between cell death and mitotic duration, suggesting that cell fate after treatment with antimitotic drugs is not exclusively dictated by mitotic length.65 Gascoigne and Taylor proposed an elegant model based on two competing networks, one that involves mitotic cell death pathways and other that regulates cyclin B1 degradation. These two networks have specific thresholds that compete during mitotic arrest. If cyclin B1 levels fall under a certain threshold before caspase activation has reached its cell death threshold, then cells will exit from mitosis. On the other hand, if cyclin B1 levels fall slowly, then cell death threshold will be achieved first and cells will die in mitosis.69
According with this model, it is predictable that completely blocking mitotic exit might be a powerful strategy to induce mitotic cell death. We have recently demonstrated that impairing cyclin B1 degradation in vivo by genetic elimination of Cdc20 is much more efficient in killing tumor cells than targeting the spindle assembly with classical poisons or new drugs inhibiting Eg5 or Plk1.70 These observations are in agreement with the pioneer results using RNA interference (RNAi) against Cdc20 or expressing a non-degradable mutant of cyclin B1 in several tumor cell lines.71 Whereas classical antimitotic drugs (vincristine or taxol) and new available mitotic inhibitors against Plk1 or kinesin Eg5 (BI2536 or monastrol, respectively) only induce a partial response in aggressive tumors, Cdc20 ablation results in complete metaphase arrest, leading to massive apoptotic cell death and complete tumor elimination in vivo.70 Importantly, mitotic exit inhibition also affects pRb-null, p53-null or SAC-deficient cells,70, 71 suggesting widespread uses. In vitro, Cdc20-null tumor cells cannot escape from the metaphase arrest and die of mitotic cell death in 6-30 h.70 Altogether, these results suggest that drugs that target Cdc20 or other components involved in cyclin B1 degradation, such as core components of the APC/C or the proteasome, could be quite effective in killing tumor cells. Indeed, a genome-wide RNAi screen has recently identified synthetic lethal interaction between K-RAS oncogenic signaling and the inhibition of core subunits of the APC/C, such as APC1 and APC472. These results have been reinforced with the discovery of tosyl-L-arginine methyl ester (TAME), an APC/C small-molecule inhibitor that efficiently arrests tumor cells in mitosis triggering cell death.73
Although targeting mitotic exit may be highly efficient, how can this strategy discriminate between tumor and normal proliferating cells? As previously suggested, APC/C–Cdc20 inhibitors could be useful in combination with other mitotic poisons by slowing cyclin B1 degradation and thus providing enough time to reach the apoptotic threshold of tumor cells.67 Other strategies to consider are those orientated to protect normal proliferating cells by impairing their entry into mitosis. Some studies proposed to use Cdk2/4 inhibitors to arrest pRb-proficient cells in G0/G1 and protect them from mitotic exit inhibitors. In contrast, pRb-null tumor cells would overcome this arrest, thereby making them sensitive to arrest and die in mitosis.74 Other studies using xenotransplanted tumors have demonstrated that prolonged fasting dramatically reduces the toxic side effects of chemotherapy, while maintaining its efficacy against tumor cells.75 All these strategies could help to improve the therapeutic window of antimitotic therapies, making them tumor selective.
An interesting question that rises from these studies is whether tumors cells treated with APC/C inhibitors may adapt to this situation and what would be the molecular requirements for this resistance. In our previous work, we have shown that kinases Cdk1 and Mastl are required for Cdc20-dependent metaphase arrest and apoptosis. Cdk1 and Mastl inhibition strongly synergizes to promote exit from mitosis and tumor cell survival in vitro.70 Thus, whereas APC/C inhibition may enhance the therapeutic benefits of specific mitotic drugs, inhibition of Cdk1 or Mastl should be avoided. In summary, targeting mitotic exit offers effective possibilities for killing tumor cells, and further investigation will be required to identify druggable targets and to validate this therapeutic strategy in specific tumors in vivo.
Molecular Pathways of Mitotic Cell Death
Cells treated with antimitotic drugs exhibit a prometaphase delay, due to SAC activity, that is often followed by mitotic cell death. Although the link between mitotic arrest and apoptosis is well established, the molecular determinants of this apoptotic response are mostly unknown. For a long time, the activity of the mitotic checkpoint has been suspected to be required to kill tumor cells treated with spindle poisons.29 Consistent with these observations, the mitotic checkpoint protein BubR1 has shown proapoptotic activity in polyploid cells that escaped from prolonged mitotic arrest.76 However, studies using Cdc20-deficient cells, in which the mitotic checkpoint is satisfied, have proved that the mere SAC activity is not required for inducing mitotic cell death (Figure 2). Consequently, a proapoptotic signal independent of the SAC accumulates to trigger apoptosis during mitotic arrest.70, 71 Recent data suggest that caspases are not required for the activity of the mitotic checkpoint or for mitotic slippage,77 suggesting that mitotic and death pathways are two independent processes. How these two processes talk to each other and how cell death is triggered and modulated during prolonged mitosis is a central question that needs to be answered.
Mitotic cell death generally occurs via intrinsic or mitochondrial apoptosis, which is regulated by the Bcl-2 family of proteins.78 Prosurvival members, including Bcl-XL, Bcl-2 and Mcl-1, antagonize apoptosis by blocking the activity of proapoptotic regulators. On the other hand, proapoptotic members, Bax and Bak, function as mediators of mitochondrial membrane permeability, allowing the activation of caspases, the proteases that catalyze cellular death. Interestingly, cyclin B1–Cdk1 may have a central role in the regulation of these apoptotic proteins (Figure 3). Cdk1 has been shown to phosphorylate both Bcl-XL and Bcl-2, leading to the inactivation of their antiapoptotic activities.79 During a normal mitosis, transient activation of Cdk1 fails to reach the phosphorylation threshold that overrides the antiapoptotic activity of these regulators. However, if Cdk1 is active for too long, the threshold is reached, causing inactivation of the antiapoptotic function and eventual apoptosis.79 Recent studies have also elucidated a new role of Cdk1 in controlling the turnover of Mcl-1. Phosphorylation of Mcl-1 makes it sensitive to its polyubiquitination by the Skp–Cullin–F-box protein complex (SCF; Figure 3). Once Mcl-1 is phosphorylated by JNK, p38 and CKII kinases, it is recruited to the SCF by the tumor suppressor protein Fbw7 and degraded by the proteasome. During normal mitosis, phosphorylation of Mcl-1 is counteracted by phosphatases such as PP2A. However, upon extended mitosis, Cdk1 promotes T92 phosphorylation and PP2A dissociation of Mcl-1, allowing its Fbw7-dependent degradation.80 Mcl-1 has also been reported to be degraded by APC/C–Cdc20 when it is phosphorylated by Cdk1 in mitotic arrested cells.81 Thus, by promoting degradation of Mcl-1 in mitotic arrested cells, Cdk1 allows the activation of Bax and Bak proteins to promote mitotic cell death. Furthermore, the lengthened activation of Cdk1 may increase the activity of p53, which causes the transcription of proapoptotic proteins such as Bax and Puma, thereby initiating mitochondrial apoptosis.82 In contrast, Cdk1 may also phosphorylate caspase-9 and caspase-8, hampering their ability to trigger the intrinsic or extrinsic apoptotic pathways, respectively.83, 84 Altogether, these data suggest that cyclin B1–Cdk1 complexes have a key role in balancing survival and cell death pathways that dictate the fate of cells during mitotic arrest. How the proapoptotic and prosurvival activities of Cdk1 are controlled is not clear at present.
The therapeutic relevance of targeting the apoptotic machinery has already been shown by using BH3 mimetics. These compounds function as inhibitors of prosurvival members of the Bcl-2 family and have demonstrated efficacy against either tumor cell lines or xenografted human tumors.85 In addition, BH3 mimetics increase the efficacy of microtubule poisons, suggesting a role for Bcl-2 proteins in mitotic cell death.86 Although apoptosis seems to be the main mechanism by which cells die after an extended mitotic arrest, the fact that caspase inhibitors, such as Z-VAD.fmk, or Bcl-2 overexpression fail to completely prevent cell death induced by treatment with spindle poisons has led to conclude that other mechanisms may have a role in mitotic cell death.71, 87 From a molecular point of view, mitotic cell death may differ from classical apoptosis in the activation of a particular mitochondrial permeabilization pathway. During mitotic arrest, caspase-2 stimulates mitochondrial membrane permeabilization, facilitating the release of several caspase activators that finally lead to caspase-3 activation, one of the main death effectors in apoptosis.82 Bid cleavage has been proposed to be the main activity by which caspase-2 induces mitochondrial permeability.88 However, Cdk1 also phosphorylates caspase-2, preventing its ability to trigger apoptosis,89 and how caspase-2 is activated during mitotic arrest therefore remains unknown.
After several decades of research, our understanding of the regulation of mitosis is quite advanced, and it has allowed the identification and characterization of novel mitotic targets and strategies for clinical use. A significant number of small-molecule inhibitors against Cdks, Plk1, Aurora kinases, Mps1, Eg5 or the APC/C are now available for preclinical or clinical studies (Table 1). The initial clinical trials with some of these compounds have confirmed efficacy in vivo, but in most cases worse than classical microtubule-targeting drugs. The basis for these differences are not clear, although we believe that our scarce knowledge of the in vivo requirements for some of these targets, the need for improvement in specificity and potency of the current compounds, and the lack of biomarkers to select patients may explain the limited effect observed so far. Given the fact that the majority of human tumors divide very slowly, compared with cultured cell lines and tumors in animal models, it has been speculated that the success of microtubule poisons might be given by its ability to target non-mitotic functions of microtubules.90 Irrespectively of the molecular details behind the success of these classical microtubule poisons, it is now clear that additional strategies, such as targeting the mitotic checkpoint or blocking mitotic exit, are emerging possibilities that deserve further exploration. Targeting CIN or aneuploidy is also being considered (Box 1), although further molecular and in vivo research are required to establish clear pathways and properly validate targets. The goal in most of these strategies is killing cancer cells. However, it is actually surprising how insufficient is our knowledge on the molecular pathways that modulate mitotic cell death and the differences between this type of death and other forms of apoptosis. Mitosis and apoptosis researchers need to combine efforts for moving forward in this direction in the future.
The Cell Division and Cancer group of the CNIO is supported by the Association for International Cancer Research (AICR no. 08-0188), Foundation Ramón Areces, the OncoCycle Programme (S-BIO-0283-2006) from the Comunidad de Madrid, the Spanish Ministry of Science and Innovation (SAF2009-07973 and OncoBIO Consolider-Ingenio 2010 Programme (CSD2007-00017)) and the European Union Seventh Framework Programme (MitoSys project; HEALTH-F5-2010-241548).
spindle assembly checkpoint
Skp–Cullin–F-box protein complex
About this article
6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability
Cancer Chemotherapy and Pharmacology (2019)